Literature DB >> 3166115

Intrathecal humoral immunologic response in neurologically symptomatic and asymptomatic patients with human immunodeficiency virus infection.

I Elovaara1, I Seppälä, E Poutiainen, J Suni, S L Valle.   

Abstract

We analyzed the intrathecal humoral immunologic response in 42 human immunodeficiency virus (HIV)-infected patients. Eighteen patients had clinical neurologic abnormalities, while the remaining 24 patients were neurologically symptom-free. Nine of the neurologically symptomatic patients at early infection had slight neurologic dysfunction; in nine other subjects at late infection, the neurologic impairment was moderate or severe. When compared with symptom-free patients, neurologically symptomatic patients had increased intra-blood-brain barrier (BBB) HIV-specific IgG (p less than 0.001) and total IgG synthesis (p less than 0.01) with oligoclonal bands (OCBs) in the CSF and/or serum (11/18 versus 3/24). At early stages of the infection, neurologically symptomatic patients showed increased total intrathecal IgG synthesis (9/9) coincident with OCBs in the CSF and serum (7/9) and slight mononuclear pleocytosis (7/9), but less frequent HIV-specific IgG production within the CNS (6/9). In advanced infection, the number of neurologically symptomatic patients with intrathecal HIV-specific IgG synthesis (8/9) was higher, while the number of those with increased total intra-BBB IgG synthesis (5/9; p less than 0.01), OCBs (4/9), and increased CSF leukocyte count (1/9; p less than 0.001) was lower than at early infection. Our data suggest humoral intra-BBB immunoactivation at early stages of HIV infection followed by declining B cell response within the CNS at advanced infection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3166115     DOI: 10.1212/wnl.38.9.1451

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  8 in total

1.  Radiological study of the brain at various stages of human immunodeficiency virus infection: early development of brain atrophy.

Authors:  R Raininko; I Elovaara; A Virta; L Valanne; M Haltia; S L Valle
Journal:  Neuroradiology       Date:  1992       Impact factor: 2.804

Review 2.  [HIV 1-associated neurocognitive disorder: current epidemiology, pathogenesis, diagnosis and management].

Authors:  C Eggers
Journal:  Nervenarzt       Date:  2014-10       Impact factor: 1.214

3.  Intrathecal humoral responses are inversely associated with the frequency of simian immunodeficiency virus macrophage-tropic variants in the central nervous system.

Authors:  Elena Ryzhova; Pyone Aye; Tom Harvey; Wei Cao; Andrew Lackner; Francisco González-Scarano
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

Review 4.  Cerebrospinal fluid (CSF) analyses in HIV-1 primary neurological disease.

Authors:  J Nogales-Gaete; K Syndulko; W W Tourtellotte
Journal:  Ital J Neurol Sci       Date:  1992-11

Review 5.  Acquired immune deficiency syndrome in childhood. Neurological aspects.

Authors:  P Iannetti; P Falconieri; C Imperato
Journal:  Childs Nerv Syst       Date:  1989-10       Impact factor: 1.475

6.  Normalisation of cerebrospinal fluid biomarkers parallels improvement of neurological symptoms following HAART in HIV dementia--case report.

Authors:  Lars-Magnus Andersson; Lars Hagberg; Lars Rosengren; Dietmar Fuchs; Kaj Blennow; Magnus Gisslén
Journal:  BMC Infect Dis       Date:  2006-09-15       Impact factor: 3.090

Review 7.  Compartmentalized intrathecal immunoglobulin synthesis during HIV infection - a model of chronic CNS inflammation?

Authors:  Mickael Bonnan; Bruno Barroso; Stéphanie Demasles; Elsa Krim; Raluca Marasescu; Marie Miquel
Journal:  J Neuroimmunol       Date:  2015-05-16       Impact factor: 3.478

Review 8.  HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment.

Authors:  Christian Eggers; Gabriele Arendt; Katrin Hahn; Ingo W Husstedt; Matthias Maschke; Eva Neuen-Jacob; Mark Obermann; Thorsten Rosenkranz; Eva Schielke; Elmar Straube
Journal:  J Neurol       Date:  2017-05-31       Impact factor: 4.849

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.